Chemical engineers boost bacteria’s productivity

MIT chemical engineers have designed a novel genetic switch that allows them to dramatically boost bacteria’s production of useful chemicals by shutting down competing metabolic pathways in the cells. In a paper appearing in the Feb. 13 issue of Nature Biotechnology, the researchers showed that they could significantly enhance the yield of glucaric acid, a chemical that is a precursor to products such as nylons and detergents. This genetic switch could also be easily swapped into bacteria that generate other products, the researchers say.

Spotlight

Marcyrl Pharmaceutical Industries

Marcyrl was established since 1998 as a simple private company “Marcyrl Import & Export Company”. On Jan 17, 2002 and according to Law no. 491 /2002, Marcyrl has received Ministry of health approval to build the factory. Marcyrl is committed to discover, research, develop and manufacture recently generic products and acquire new products to be manufactured under license from Multinational Companies at our facility.

OTHER ARTICLES
MedTech

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | October 7, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More
MedTech

Data Analytics: A Groundbreaking Technology in Biotech

Article | July 16, 2022

Biotechnology is a vast discipline of biology that employs diverse biological systems to create solutions that can significantly alter the ways in which they operate across various domains. That said, biotechnology is not a new notion. It has existed for millennia, with ancient civilizations using its earliest incarnations to cultivate crops and create alcoholic beverages. Today, the biotechnology industry has developed by leaps and bounds and has amassed a vast quantity of scientific data through study and research. Given the importance of data in the biotechnology business, it is not difficult to understand why biotech companies utilize data analytics. Modern data analytics tools have made it possible for researchers in the biotech industry to build predictive analytics models and gain knowledge about the most efficient approaches to accomplish their desired goals and objectives. Data analytics is increasingly being adopted by biotech businesses to better understand their industry and foresee any problems down the road. How is Data Analytics Revolutionizing Fields in Biotechnology? Today's business and scientific fields greatly benefit from data. Without the analysis of vast information libraries that provide new insights and enable new innovations, no industry can really advance. Being highly reliant on big data analytics, biotech is not an exception in this regard. With the tools and methods that help scientists systematize their findings and speed up their research for better and safer results, data analytics is making deeper inroads into the biotechnology industry. It is emerging as a crucial link between knowledge and information and is extensively being used for purposes other than just examining the information that is already available. The following are a few of the cutting-edge biotechnology applications of data analytics Genomics and Disease Treatment Pharmaceutical Drug Discovery Drug Recycling and Safety Agriculture and Agri-products Environmental Damage Mitigation Data Analytics Possibilities in Biotechnology With data analytics becoming an integral part of how biotech businesses operate, biotechnologists and related stakeholders need to understand its emergence and crucial role. Data analytics has opened new frontiers in the realm of biotechnology. Thanks to developments in data analytics, research and development activities that once took years may now be accomplished in a matter of months. Also, now scientists have access to biological, social, and environmental insights that can be exploited to create more effective and sustainable products. By understanding the importance of data-related tools and techniques applications, biotech companies are aiming to invest in the popularizing technology to stay updated in the fast-paced biotechnology industry.

Read More
MedTech

Expansion of BioPharma: Opportunities and Investments

Article | September 22, 2022

Biopharmaceutical innovations are among the most ingenious and refined achievements of modern medical science. New concepts, techniques, and therapies are emerging, such as the cell therapy Provenge, which can be used to treat cancer, and gene therapies, which provide even more amazing promises of disease remission and regenerative medicine. In addition, the COVID-19 pandemic has caused a huge boom in the pharmaceutical industry. This is because more and more attention is being paid to increasing manufacturing capacity and starting new research on drug development. Biopharma: Leading the Way in the Pharma Sector In the past couple of years, the biopharmaceutical sector has deepened its roots across the medical and pharmaceutical industries, on account of the transformation of pharmaceutical companies towards biotechnology, creating opportunities for growth. Also, growing advancements in technologies such as 3D bioprinting, biosensors, and gene editing, along with the integration of advanced artificial intelligence and virtual and augmented reality are estimated to further create prospects for growth. According to a study, the biopharmaceutical sector makes nearly $163 billion around the world and grows by more than 8% each year, which is twice as fast as the traditional pharma sector. Massive Investments Directed Towards Biopharma Investing in biotech research and development (R&D) has yielded better returns than the pharma industry average. Hence, a number of pharmaceutical companies are shifting their presence toward biopharma to capitalize on the upcoming opportunities by investing in and expanding their biotechnology infrastructure. For instance, Thermo Fisher Scientific Inc., an American manufacturer of scientific instrumentation, reagents and consumables, and software services, announced an investment of $97 million to expand its bioanalytical laboratory operations into three new locations in the U.S. With this investment, the company will add 150,000 square feet of scientific workspace and install the most advanced drug development technologies to produce life-changing medicines for patients in need.

Read More
Medical

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | June 22, 2022

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More

Spotlight

Marcyrl Pharmaceutical Industries

Marcyrl was established since 1998 as a simple private company “Marcyrl Import & Export Company”. On Jan 17, 2002 and according to Law no. 491 /2002, Marcyrl has received Ministry of health approval to build the factory. Marcyrl is committed to discover, research, develop and manufacture recently generic products and acquire new products to be manufactured under license from Multinational Companies at our facility.

Related News

New strategy for cancer therapy spells double trouble for tumors

Medical Xpress | July 25, 2018

Scientists at Scripps Research have uncovered a new strategy to kill tumors, including some triple-negative breast cancers, without harming healthy cells, a discovery that could lead to more ways to treat tumors while reducing side effects. The study, published recently in Nature Communications, shows that a molecule in cells, called Rad52, repairs special kinds of damaged DNA that accumulate in some cancers. A future therapeutic could inhibit Rad52, robbing cancer cells of this repair mechanism. "This could give us a way to kill tumors without harming normal cells," says Xiaohua Wu, Ph.D., the professor at Scripps Research and senior author of the study. "That's the future. That's the goal for targeted cancer treatments—to make these treatments a part of precision medicine." Wu and her colleagues investigate how seemingly healthy cells become cancerous, with an eye toward leveraging differences between cancers and healthy cells to develop new therapeutic approaches. The culprits may be different from patient to patient, so the key to killing specific cancer types is to study the basic roles of proteins—and how things go awry in different cancers.

Read More

Rise of the clones study identifies inherited and acquired mutations that drive precancerous blood condition

Medical Xpress | July 11, 2018

A new study led by researchers at Harvard Medical School and the Harvard T.H. Chan School of Public Health has identified some of the first knowns inherited genetic variants that significantly raise a person's likelihood of developing clonal hematopoiesis, an age-related white blood cell condition linked with higher risk of certain blood cancers and cardiovascular disease.The findings, published online July 11 in Nature, should help illuminate several questions about clonal hematopoiesis: how it arises, why it occurs in more than 10 percent of people over 65 and how the genome we inherit influences the mutations we acquire later in life.

Read More

The mechanisms of genetic diversification in Candida albicans

Phys.org | July 10, 2018

Candida albicans is one of the most formidable fungal species infecting humans. Investigating the structure and reproduction methods of pathogenic populations can reveal how they emerge and spread. A team of scientists has sequenced and analyzed the genomes of 182 strains of C. albicans from around the world. They confirmed the clonal reproduction of this C. albicans and also showed that parasexual reproduction, previously only observed in a laboratory setting, contributes to its genetic diversity, and therefore also to its ability to adapt to new environments and rid itself of deleterious mutations.

Read More

New strategy for cancer therapy spells double trouble for tumors

Medical Xpress | July 25, 2018

Scientists at Scripps Research have uncovered a new strategy to kill tumors, including some triple-negative breast cancers, without harming healthy cells, a discovery that could lead to more ways to treat tumors while reducing side effects. The study, published recently in Nature Communications, shows that a molecule in cells, called Rad52, repairs special kinds of damaged DNA that accumulate in some cancers. A future therapeutic could inhibit Rad52, robbing cancer cells of this repair mechanism. "This could give us a way to kill tumors without harming normal cells," says Xiaohua Wu, Ph.D., the professor at Scripps Research and senior author of the study. "That's the future. That's the goal for targeted cancer treatments—to make these treatments a part of precision medicine." Wu and her colleagues investigate how seemingly healthy cells become cancerous, with an eye toward leveraging differences between cancers and healthy cells to develop new therapeutic approaches. The culprits may be different from patient to patient, so the key to killing specific cancer types is to study the basic roles of proteins—and how things go awry in different cancers.

Read More

Rise of the clones study identifies inherited and acquired mutations that drive precancerous blood condition

Medical Xpress | July 11, 2018

A new study led by researchers at Harvard Medical School and the Harvard T.H. Chan School of Public Health has identified some of the first knowns inherited genetic variants that significantly raise a person's likelihood of developing clonal hematopoiesis, an age-related white blood cell condition linked with higher risk of certain blood cancers and cardiovascular disease.The findings, published online July 11 in Nature, should help illuminate several questions about clonal hematopoiesis: how it arises, why it occurs in more than 10 percent of people over 65 and how the genome we inherit influences the mutations we acquire later in life.

Read More

The mechanisms of genetic diversification in Candida albicans

Phys.org | July 10, 2018

Candida albicans is one of the most formidable fungal species infecting humans. Investigating the structure and reproduction methods of pathogenic populations can reveal how they emerge and spread. A team of scientists has sequenced and analyzed the genomes of 182 strains of C. albicans from around the world. They confirmed the clonal reproduction of this C. albicans and also showed that parasexual reproduction, previously only observed in a laboratory setting, contributes to its genetic diversity, and therefore also to its ability to adapt to new environments and rid itself of deleterious mutations.

Read More

Events